# Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)

> **NCT00271713** · PHASE4 · COMPLETED · sponsor: **Charite University, Berlin, Germany** · enrollment: 70 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** ibandronate, calcium and vitamin D
- **DRUG:** placebo,calcium and vitamin D

## Key facts

- **NCT ID:** NCT00271713
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2009-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00271713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00271713, "Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00271713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*